Vaccination of patients with allergic disease against novel coronavirus infection: position paper of the Russian Association of Allergology and Clinical Immunology

封面

如何引用文章

全文:

详细

One of the key tasks of the previous year is to stop the spread of coronavirus disease (COVID-19), which became a pandemic that led to the deaths of more than 4 million people worldwide and more than 140 thousand deaths in Russia. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (2019-nCoV) virus of the coronavirus family. Vaccination plays a leading role in ending the pandemic. Currently, five vaccines against COVID-19 have been registered in Russia, namely, Sputnik V, Sputnik light, EpiVacCorona, EpiVacCorona-Н, and СoviVak. The short follow-up period and absence of randomized placebo-controlled trials of COVID-19 vaccines in certain patients with chronic diseases lead to several questions about the effectiveness/safety of vaccination in these patients. Given the wide spread of allergic diseases and the heterogeneity of patients with allergopathology, experts of the Russian Association of Allergology and Clinical Immunology have developed and approved a position paper on vaccination of patients with allergopathology.

作者简介

Natalya Ilyina

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN 代码: 6715-5650

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 24 Kashirskoe shosse, Moscow, 115522; Moscow

Oksana Kurbacheva

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN 代码: 5698-6436

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 24 Kashirskoe shosse, Moscow, 115522; Moscow

Elena Latysheva

National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia; Pirogov Russian National Research Medical University

编辑信件的主要联系方式.
Email: ealat@mail.ru
ORCID iD: 0000-0002-1606-205X
SPIN 代码: 2063-7973

MD, Dr. Sci. (Med.)

俄罗斯联邦, 24, Kashirskoye shosse, Moscow, 115522; Moscow

Tatiana Latysheva

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: tvlat@mail.ru
ORCID iD: 0000-0003-1508-0640
SPIN 代码: 8929-7644

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 24 Kashirskoe shosse, Moscow, 115522; Moscow

Evgeniya Nazarova

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ev.nazarova@nrcii.ru
ORCID iD: 0000-0003-0380-6205
SPIN 代码: 4788-7407

MD, Cand. Sci. (Med.)

俄罗斯联邦, 24 Kashirskoe shosse, Moscow, 115522

Natalia Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN 代码: 3363-6170

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Elena Fedenko

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN 代码: 5012-7242

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 24 Kashirskoe shosse, Moscow, 115522

Musa Khaitov

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Pirogov Russian National Research Medical University

Email: mr.khaitov@nrcii.ru
ORCID iD: 0000-0003-4961-9640
SPIN 代码: 3199-9803

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

俄罗斯联邦, 24 Kashirskoe shosse, Moscow, 115522; Moscow

Natalia Shartanova

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: nshartanova@yandex.ru
ORCID iD: 0000-0002-1197-9002
SPIN 代码: 6483-8901

MD, Dr. Sci. (Med.)

俄罗斯联邦, 24 Kashirskoe shosse, Moscow, 115522

参考

  1. World Health Organization. Coronavirus disease (COVID-19) pandemic. (In Russ). Available from: https://www.who.int/. Accessed: Aug 15, 2021.
  2. American Academy of Allergy, Asthma & Immunology. Allergen immunotherapy and COVID-19/SARS-CoV-2 vaccination. (In Russ). Available from: https://www.aaaai.org/Allergist-Resources/Ask-the-Expert/Answers/Old-Ask-the-Experts/allergenimm. Accessed: Aug 15, 2021.
  3. American Academy of Allergy, Asthma & Immunology. COVID vaccine reaction in a patient with asthma. (In Russ). Available from: https://www.aaaai.org/Allergist-Resources/Ask-the-Expert/Answers/Old-Ask-the-Experts/covidvreac. Accessed: Aug 15, 2021.
  4. Global Initiative for Asthma. GINA guidance about COVID-19 and asthma, updated 30 March 2021. GINA Global Strategy for Asthma Management and Prevention. (In Russ). Available from: https://ginasthma.org/wp-content/uploads/2021/03/21_03_30-GINA-COVID-19-and-asthma.pdf. Accessed: Aug 15, 2021.
  5. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–820. doi: 10.1542/peds.112.4.815
  6. Jutel M, Torres MJ, Palomares O, et al. COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics ― EAACI recommendations. Authorea. June 24, 2021. doi: 10.22541/au.162452341.15060228/v1
  7. Klimek L, Bergmann KC, Brehler R, et al. Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe: Ein Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA), der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA) und der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI). [In German] Allergo J. 2021;30(3):22–43. doi: 10.1007/s15007-021-4773-1.
  8. The procedure for vaccination of the adult population against COVID-19. Temporary methodological recommendations. Moscow; 2021.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Pharmarus Print Media, 2021

##common.cookie##